Showing 1,261 - 1,280 results of 35,226 for search '(( 5 ((point decrease) OR (nn decrease)) ) OR ( 50 ((mean decrease) OR (a decrease)) ))', query time: 0.92s Refine Results
  1. 1261
  2. 1262

    Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  3. 1263

    Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  4. 1264
  5. 1265
  6. 1266
  7. 1267
  8. 1268
  9. 1269
  10. 1270
  11. 1271
  12. 1272
  13. 1273
  14. 1274
  15. 1275
  16. 1276

    Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

    Published 2025
    “…At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD<sub>EROD,28dph</sub> of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD<sub>length,28dph</sub> of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. A toxicity pathway model constructed from genes and apical end points exhibiting concentration-dependent responses provided further evidence supporting the utility of tPODs from short-term RBT early-life-stage assay to support chemical risk assessment to guide decision-makers in chemical testing prioritization.…”
  17. 1277
  18. 1278

    BpiB09 affects the QS-dependent pyocyanin production, <i>C. elegans</i> paralysis in PAO1 and decreases AHL response in <i>A. tumefaciens</i> AHL reporter strain. by Patrick Bijtenhoorn (199146)

    Published 2011
    “…<p><b>A</b>) Decreased pyocyanin production. OD<sub>520</sub> of pyocyanin extracts from culture supernatants of <i>P. aeruginosa</i> carrying pBBR1MCS-5::<i>bpiB09</i> and empty pBBR1MCS-5. …”
  19. 1279
  20. 1280